Humana (NYSE:HUM) Upgraded at StockNews.com

Humana (NYSE:HUM - Get Free Report) was upgraded by research analysts at StockNews.com from a "hold" rating to a "buy" rating in a research note issued to investors on Friday.

HUM has been the topic of several other reports. Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research report on Wednesday, January 15th. Oppenheimer increased their price objective on shares of Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a report on Thursday, May 1st. Guggenheim began coverage on shares of Humana in a report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 target price on the stock. Truist Financial boosted their target price on Humana from $290.00 to $325.00 and gave the stock a "hold" rating in a research report on Friday, April 11th. Finally, Raymond James raised Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a report on Thursday, May 1st. Seventeen research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, Humana currently has an average rating of "Hold" and an average price target of $287.76.

Humana Stock Performance

NYSE:HUM traded down $3.68 on Friday, hitting $249.67. The stock had a trading volume of 1,087,102 shares, compared to its average volume of 1,745,516. The business's 50-day simple moving average is $265.21 and its two-hundred day simple moving average is $270.38. Humana has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market cap of $30.13 billion, a price-to-earnings ratio of 25.09, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. The firm had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. The business's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter last year, the company earned $7.23 earnings per share. As a group, research analysts predict that Humana will post 16.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HUM. Dodge & Cox increased its holdings in Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock valued at $2,587,345,000 after buying an additional 5,264,045 shares during the period. Vanguard Group Inc. increased its position in Humana by 15.8% during the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock valued at $3,254,899,000 after buying an additional 1,751,857 shares in the last quarter. Norges Bank purchased a new stake in shares of Humana during the fourth quarter worth about $416,202,000. Pzena Investment Management LLC boosted its stake in Humana by 44.0% in the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock worth $915,736,000 after purchasing an additional 1,103,132 shares in the last quarter. Finally, Boston Partners raised its holdings in shares of Humana by 435.8% in the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider's stock worth $279,236,000 after buying an additional 893,637 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.